Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq 2.0 and an in-house method.
Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq 2.0 and an in-house method.
复制标题
DOI：
10.1016/j.jviromet.2009.03.021
复制
发表时间：
2009-08
影响因子：
3.1
通讯作者：
Mayer KH
中科院分区：
文献类型：
--
作者：
Saravanan S;Vidya M;Balakrishnan P;Kumarasamy N;Solomon SS;Solomon S;Kantor R;Katzenstein D;Ramratnam B;Mayer KH
商业HIV-1基因型耐药检测非常昂贵，特别是在印度等资源受限的环境中使用。因此，采用标准ViroSeq™HIV-1基因分型系统2.0 （Celera Diagnostics， CA， USA）验证了一种具有成本效益的内部耐药检测方法。总共使用了50个样本进行评估（21个熟练程度小组和29个临床分离株）。包括HIV-1蛋白酶（PR）区（1-99个密码子）和HIV-1逆转录酶（RT）区（1-240个密码子）内已知的抗性位点。对每个密码子的分析结果如下：(i)一致性；（ii）部分一致；（iii）不确定和（iv）不一致。共分析了2750个与耐药相关的密码子（每个患者样本55个密码子× 50个样本）（1050个PR和1700个RT）。对于PR， 99%的密码子结果一致，1%的密码子结果部分一致。对于RT， 99%的密码子结果一致，0.9%部分一致，0.1%不一致。未观察到不确定结果，结果可重复性好。总体而言，内部分析提供的结果与美国FDA批准的ViroSeq™相当，其成本约为商业分析的一半（100美元对230美元），使其适合资源有限的环境。
Commercial HIV-1 genotypic resistance assays are very expensive, particularly for use in resource-constrained settings like India. Hence a cost effective in-house assay for drug resistance was validated against the standard ViroSeq™ HIV-1 Genotyping System 2.0 (Celera Diagnostics, CA, USA). A total of 50 samples were used for this evaluation (21 proficiency panels and 29 clinical isolates). Known resistance positions within HIV-1 protease (PR) region (1–99 codons) and HIV-1 reverse-transcriptase (RT) region (1–240 codons) were included. The results were analysed for each codon as follows: (i) concordant; (ii) partially concordant; (iii) indeterminate and (iv) discordant. A total of 2750 codons (55 codons per patient sample × 50 samples) associated with drug resistance (1050 PR and 1700 RT) were analysed. For PR, 99% of the codon results were concordant and 1% were partially concordant. For RT, 99% of the codon results were concordant, 0.9% were partially concordant and 0.1% were discordant. No indeterminate results were observed and the results were reproducible. Overall, the in-house assay provided comparable results to those of US FDA approved ViroSeq™, which costs about a half of the commercial assay ($ 100 vs. $ 230), making it suitable for resource-limited settings.
登录
查看更多内容
影响因子：
9.4
作者：
Beek, IA;Mahalanabis, M;Frenkel, LM
通讯作者：
Frenkel, LM
针对恩夫韦肽耐药 HIV-1 菌株的有效 HIV 融合抑制剂
DOI：
10.1073/pnas.0807335105
发表时间：
2008-10-21
影响因子：
11.1
作者：
He, Yuxian;Cheng, Jianwei;Dai, Qiuyun
通讯作者：
Dai, Qiuyun
影响因子：
1.5
作者：
Church, Jessica D.;Towler, William I.;Eshleman, Susan H.
通讯作者：
Eshleman, Susan H.
影响因子：
11.8
作者：
Kent, DM;McGrath, D;Bennish, ML
通讯作者：
Bennish, ML
影响因子：
9.5
作者：
Kumar, S;Tamura, K;Nei, M
通讯作者：
Nei, M